基因技术正驱动新一轮产业革命，其先行领域基因检测技术已从科研迈向临床，并向消费级居家检测拓 展 充分发挥中国超大规模市场优势，以规模化应用场景驱动技术创新与迭代，加速基因技术在精准医疗、 健康管理等领域的深度应用，抢占未来生物经济制高点 充分发挥基因技术的底层技术、通用技术作用，为精准医学、健康管理、基础科研、教学育人、农业育 种、生物制造、细胞产业、中医药、检验检疫等领域提供工具支撑、科研合作、产业合作，孵化一系列 新技术、新设备、新服务 文 | 李斌 在北京举办的第三届中国国际供应链促进博览会上，华大集团展位展出的高通量基因检测 AI+ 本地化 医学解决方案（2025 年 7 月 16 日摄） 任超摄 / 本刊 基因技术作为生物科技基石，近年来在检测、编辑、合成、治疗等方向不断取得突破。其研发和应用不 仅具有重塑医疗、农业、环保等产业的潜力，更可望通过技术升级、产业革新和数据驱动，成为推动新 质生产力发展的关键引擎。 近年来，基因技术行业进入发展快车道，基因检测凭借"体量最大、落地最实、基础作用显著"的特点， 成为核心部分。相关专家认为，在基因检测领域，应用场景从科研服务逐步深入临床诊断，迈向消费级 居家 ...

Core Viewpoint - The company announced the progress of litigation related to the transfer of equity in Hainan Hongrun Tianyuan Gene Biotechnology Co., Ltd, indicating that the lawsuit will not adversely affect its current or future profits [1][3]. Group 1: Basic Situation of the Lawsuit - Wuhan Baitai Gene Engineering Co., Ltd and Shanghai Ruian Gene Technology Co., Ltd filed lawsuits against Beijing Hongrun Tianyuan Gene Biotechnology Co., Ltd and Guangxi Wanhou Trading Co., Ltd, claiming that the equity transfer affected their creditor rights [1]. - The Beijing Haidian District People's Court made a first-instance judgment to revoke the equity transfer of 100% of Hainan Hongrun's shares from Beijing Hongrun to Guangxi Wanhou [1]. Group 2: Progress of the Lawsuit - Both parties involved in the lawsuits appealed to the Beijing First Intermediate People's Court after being dissatisfied with the first-instance judgment [2]. - A settlement was reached among the parties during the appeal process, and the plaintiffs applied to withdraw their lawsuits during the second-instance hearing [2]. - The court issued a final ruling to revoke the first-instance judgment and allowed the plaintiffs to withdraw their lawsuits [3]. Group 3: Impact on Company Profits - The settlement and the court's decision to allow the withdrawal of lawsuits indicate that there will be no negative impact on the company's current or future profits [3]. Group 4: Other Litigation Matters - The company and its controlling entities currently have no other significant litigation or arbitration matters that need to be disclosed [3].

Group 1 - The company, Chengdu Berry Genomics Technology Co., Ltd., has agreed to provide a joint liability guarantee for its wholly-owned subsidiary, Beijing Berry Genomics Biotechnology Co., Ltd., which applied for a comprehensive credit line of 30 million yuan from the Bank of China [1] - The board of directors approved the guarantee without needing to submit it to the shareholders' meeting, as per relevant regulations [1] - The total amount of external guarantees provided by the company and its subsidiaries is 317 million yuan, accounting for 18.87% of the latest audited net assets [3][4] Group 2 - The subsidiary, Beijing Berry, has total assets of approximately 2.15 billion yuan and total liabilities of about 693.94 million yuan, resulting in net assets of approximately 1.45 billion yuan [2] - The subsidiary reported a total revenue of approximately 443.45 million yuan, with a net loss of about 29.26 million yuan [2] - The company has no overdue guarantees or litigation related to guarantees as of the announcement date [4]

Group 1: Financing & Review - In May 2025, the Beijing Stock Exchange (BSE) issued 1 new stock, raising 168 million yuan; a total of 4 new stocks were issued from January to May 2025, raising a cumulative 1.702 billion yuan[5] - As of the end of May, there were 11 companies that had passed the review but not yet registered, with a proposed fundraising amount of 2.511 billion yuan; 1 company was registered but not yet issued, with a proposed fundraising of 200 million yuan[5] - The average proposed fundraising amount for companies under review is approximately 250 million yuan, with a total expected fundraising of 7.5 billion yuan for the year based on historical data[5] Group 2: Subscription & Issuance - In May 2025, 10 new companies were accepted for review, with 3 passing and 3 terminating; the acceptance rate shows a month-on-month increase[5] - The average first-day increase for new stocks in May was 441.68%, with a theoretical subscription return of 0.177%[3] - The cumulative return for new stock subscriptions from January to May 2025 was 0.50%, while the cumulative return for 2024 was 3.99%[3] Group 3: Market Trends & Predictions - The expected first-day increase for new stocks is set at 200%, with scenarios considering increases of 100%, 200%, and 300%[5] - The average online subscription amount in May was 7.99 million yuan, with a minimum investment threshold of 2.85 million yuan[34] - The online subscription rate is projected to be 0.056%, with variations based on different levels of frozen funds[5] Group 4: Investment Analysis & Risks - The high enthusiasm for new stock subscriptions is suppressing the subscription rate, which was only 0.03% in May due to the low fundraising amounts[5] - Risks include slower-than-expected issuance speed, lower-than-expected stock price increases, and potential macroeconomic downturns[5]

以下文章来源于中国企业家杂志 ，作者胡楠楠 中国企业家杂志 . 讲好企业家故事，弘扬企业家精神 每一次全球经济社会的低谷，都会酝酿产业浪潮和科技革命，因为人类在 寻找新的突破口。 文 ｜《中国企业家》记者 胡楠楠 编辑 ｜米娜 头图来源 ｜中企图库 12月13日~15日，由《中国企业家》杂志社主办的"2024（第二十二届）中国企业领袖年会"在 北京举行。国内著名经济学家、泽平宏观创始人任泽平出席本次年会，围绕"新周期"这个主 题，分享了他对2025年经济趋势的洞察。 以下为核心要点： 1.每一次全球经济社会的低谷，都会酝酿产业浪潮和科技革命，因为人类在 寻找新的突破口。 2.美联储降息打开了我们货币政策宽松的窗口。时隔14年，我们重新提出适 度宽松的货币政策。 3.明年国产替代、新质生产力可能会受到空前的重视。 4.第四次科技革命可能在7个领域爆发，比如新能源、人工智能、商业航 天、生物制造、基因技术、量子信息技术、可控核聚变。 5.新能源汽车已经进入淘汰赛，下半场是智能驾驶的时代，储能、氢能的时 代，这些在未来有大把的机会。 6.提振资本市场不仅有利于提振消费，还有利于中国的创新。 以下为任泽平现场演讲实录 ...